How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Anaplastic lymphoma kinase (ALK) inhibitors have demonstrated robust clinical activity in patients with ALK-rearranged lung cancers. The echinoderm microtubule-associated protein-like (EML)-ALK translocation was first discovered in 2007 and 4 years later, crizotinib, a first-generation ALK inhibitor...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Lung Cancer Res
Asıl Yazarlar: Xia, Bing, Nagasaka, Misako, Zhu, Viola W., Ou, Sai-Hong Ignatius, Soo, Ross A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2020
Konular:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7815371/
https://ncbi.nlm.nih.gov/pubmed/33489815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-331
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller